Quarterly report pursuant to Section 13 or 15(d)

REVENUES (Tables)

v3.22.1
REVENUES (Tables)
3 Months Ended
Mar. 31, 2022
REVENUES  
Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):

Three Months Ended March 31, 

2022

    

2021

Product sales:

Gross product sales

$

22,618

$

16,109

Discounts and allowances

(6,421)

(3,733)

Total product sales, net

16,197

12,376

Revenues from collaborations:

License revenues

208

64,618

Research and development services and others

330

1,024

Total revenues from collaborations

538

65,642

Government contract

3,000

Total revenues

$

16,735

$

81,018

Schedule of product revenue allowance and reserve categories

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance as of January 1, 2022

    

$

3,404

$

2,494

$

2,017

$

7,915

Provision related to current period sales

4,345

1,397

378

6,120

Credit or payments made during the period

(3,322)

(1,227)

(31)

(4,580)

Balance as of March 31, 2022

 

$

4,427

$

2,664

$

2,364

$

9,455

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance as of January 1, 2021

    

$

2,461

 

$

2,115

$

1,489

$

6,065

Provision related to current period sales

1,952

1,146

201

3,299

Credit or payments made during the period

(2,727)

(988)

(243)

(3,958)

Balance as of March 31, 2021

 

$

1,686

$

2,273

$

1,447

$

5,406

Schedule of revenues from product sales disaggregated by customers

The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more (wherein * denotes less than 10%) of the total net product sales and revenues from collaborations:

Three Months Ended March 31, 

2022

    

2021

McKesson Specialty Care Distribution Corporation

38%

*

ASD Healthcare and Oncology Supply

31%

*

Cardinal Healthcare

28%

*

Lilly

*

78%